FDA Raps ADMA Biologics for Poor Documentation, Data Controls

Drug Industry Daily
A A
The FDA cited ADMA Biologics for failure to implement proper document controls and prevent unauthorized changes to data in its computer systems.

To View This Article:

Login

Subscribe To Drug Industry Daily